Brigatinib

布格替尼

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameBrigatinib
Drug Alias Namebrigatinibum布利替尼布加替尼AlunbrigALUNBRIG +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsProto-oncogene tyrosine-protein kinase ROS inhibitorsAnaplastic lymphoma kinase inhibitors +[5] 
TargetsInsulin-like growth factor I receptorAnaplastic lymphoma kinaseProto-oncogene tyrosine-protein kinase ROS +[5] 
Therapy Area/IndicationsBrain metastasesSolid tumoursGranuloma, Plasma Cell +[15] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2017/04/28
Country/TerritoryMainland China(BOAO LECHENG)CanadaUnited States +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAriad Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesTakeda (China) International Trading Co LtdTakeda Pharmaceuticals USA IncThe University Of Texas MD Anderson Cancer Center +[8] 
Inactive CompaniesYonsei UniversityNational Cancer InstituteUniversity Of Colorado Denver +[4] 
Active IndicationsSolid tumoursGranuloma, Plasma CellCarcinoma, Non-Small-Cell Lung +[10] 
Inactive IndicationsBrain metastasesCarcinomaMyofibroma +[5] 

Other Information

ATC CodeL01ED04
Related LinksWikipediaDrugBankKEGG